Recent Updates
Recently added Catalysts
HYFT Positive Sentiment

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MindWalk Holdings Corp. reported that its LensAI™ technology screened 890,634 antibody sequences in just 4 hours and 41 minutes. The screening was conducted on Amazon EC2 Hpc8a instances using 5th Gen AMD EPYC™ processors. This approach resulted in a cost reduction of up to 43% per sequence compared to similar Intel configurations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Screened 890,634 antibody sequences in under five hours.
  • Achieved 43% lower cost per sequence compared to Intel.
  • Utilized advanced AMD EPYC processors for efficiency.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today published a white paper showing that its LensAI™ immunogenicity screening ran across an entire public antibody database of 890,634 sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by 5th Gen AMD EPYC™ processors, delivering up to 43% lower cost per sequence than a comparable Intel configuration running identical code. “Every antibody drug carries a questio

Frequently Asked Questions

What is MindWalk's LensAI™ technology?

LensAI™ is an immunogenicity screening technology developed by MindWalk.

How long did the antibody screening take?

The screening took 4 hours and 41 minutes.

What was the cost reduction achieved?

MindWalk achieved a cost reduction of up to 43% per sequence.

Which processors powered the screening?

The screening was powered by 5th Gen AMD EPYC™ processors.

ShareAdd on Google
Tags: HYFT MindWalk antibody sequences LensAI AMD EPYC
Last updated: Oct 21, 2026